Author: cpereira@noblefcm.com

Tonix Pharmaceuticals (TNXP) – 1Q25 Reported With Preparations For TNX-102 SL Launch in 4Q25

Posted on by cpereira@noblefcm.com


Wednesday, May 14, 2025

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-15001 which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to be initiated in the second half of 2022. Tonix’s rare disease portfolio includes TNX-29002 for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan-Drug Designation by the FDA. Tonix’s infectious disease pipeline includes a vaccine in development to prevent smallpox and monkeypox called TNX-8013, next-generation vaccines to prevent COVID-19, and an antiviral to treat COVID-19. Tonix’s lead vaccine candidates for COVID-19 are TNX-1840 and TNX-18504, which are live virus vaccines based on Tonix’s recombinant pox vaccine (RPV) platform. TNX-35005 (sangivamycin, i.v. solution) is a small molecule antiviral drug to treat acute COVID-19 and is in the pre-IND stage of development. TNX-102 SL6, (cyclobenzaprine HCl sublingual tablets), is a small molecule drug being developed to treat Long COVID, a chronic post-acute COVID-19 condition. Tonix expects to initiate a Phase 2 study in Long COVID in the second quarter of 2022. The Company’s CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL, is in mid-Phase 3 development for the management of fibromyalgia with a new Phase 3 study launched in the second quarter of 2022. Finally, TNX-13007 is a biologic designed to treat cocaine intoxication that is expected to start a Phase 2 trial in the second quarter of 2022. TNX-1300 has been granted Breakthrough Therapy Designation by the FDA.

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

1Q25 Reported With Product Updates. Tonix reported a 1Q25 loss of $16.8 million or $(2.84) per share, a smaller loss than we had estimated. Product sales were $2.4 million, slightly lower than the $2.6 million in 4Q24. Gross margins were 61%, an improvement over the 54% seen in 4Q24. TNX-102 SL has a PDUFA date of August 15, and preparations continue for launch in 4Q25. Cash on hand on March 31 was $131.7 million.

Anticipation Builds For TNX-102 SL PDUFA Date. We believe the two Phase 3 trials support product approval for TNX-102 SL in its fibromyalgia indication. As we have described in previous Research Notes, fibromyalgia is currently treated with a combination of pain relievers (opioid and neurological), antidepressants, and insomnia drugs. TNX-102 SL could become the first drug to relieve all major symptoms without side effects from each class of drug.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Lucky Strike Entertainment (LUCK) – A More Sober View, But Still Positive

Posted on by cpereira@noblefcm.com


Wednesday, May 14, 2025

Lucky Strike Entertainment is one of the world’s premier location-based entertainment platforms. With over 360 locations across North America, Lucky Strike Entertainment provides experiential offerings in bowling, amusements, water parks, and family entertainment centers. The company also owns the Professional Bowlers Association, the major league of bowling and a growing media property that boasts millions of fans around the globe. For more information on Lucky Strike Entertainment, please visit ir.luckystrikeent.com.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Lackluster Q3 Results. The company reported Q3 revenue of $339.9 million and adj. EBITDA of $117.3 million, both of which were lower than our estimates of $360.0 million and $130 million, respectively. Notably, the soft results were largely driven by a decrease in corporate events in California and Seattle and partially offset by a high single-digit increase in food sales and stable retail and league business. While Q3 results were lackluster, we believe the company will gain momentum heading into the summer.

Pulls guidance. While the company did not provide guidance due to economic uncertainty, we believe that the company will demonstrate solid results in the coming quarters, supported by recent acquisitions, new centers, and strong sales in its Summer Season Pass program. Importantly, management highlighted its focus on expense management, with capital expenditures down 20% year to date, which is expected to continue into next year.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

GoHealth (GOCO) – Diversifying Revenues With A New Offering

Posted on by cpereira@noblefcm.com


Wednesday, May 14, 2025

Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q1 results. The company reported Q1 revenue of $221.0 million and adj. EBITDA of $42.1 million. The results were below our estimates of $235.0 million in revenue and $49.3 million in adj. EBITDA. Notably, the results did align with management’s previous commentary that the company would execute favorable year-over-year revenue growth in the quarter (revenue was up 19% and adj. was up 56%).

Testing final expense offering. The company recently launched GoHealth Protect, which is its guaranteed acceptance life insurance (final expense) offering. For now, the company is testing out which products fit best with consumers and what the demand function looks like across the Medicare eligible population. Importantly, as the final expense business scales, we believe it could help to balance out the company’s quarterly revenue profile, which is currently concentrated around Q4 and Q1.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

DLH Holdings (DLHC) – Refined Model

Posted on by cpereira@noblefcm.com


Wednesday, May 14, 2025

DLH delivers improved health and readiness solutions for federal programs through research, development, and innovative care processes. The Company’s experts in public health, performance evaluation, and health operations solve the complex problems faced by civilian and military customers alike, leveraging digital transformation, artificial intelligence, advanced analytics, cloud-based applications, telehealth systems, and more. With over 2,300 employees dedicated to the idea that “Your Mission is Our Passion,” DLH brings a unique combination of government sector experience, proven methodology, and unwavering commitment to public health to improve the lives of millions. For more information, visit www.DLHcorp.com.

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Refined Model. We had an opportunity to dig deep into our model with DLH management. As a result of our discussion, we revised our model. While minor, the changes do impact quarterly EPS, so we believe a model revision is instructional for investors.

Changes. We increased our D&A expense in both the third and fourth quarters to $4.25 million from our prior $4 million. In addition, we increased our fourth quarter interest expense to $3.75 million from a prior $3.5 million. We kept our tax rate at 30%. As a result of the changes, our third quarter net income and EPS declined to $350,000 and $0.02, compared to $525,000 and $0.04, respectively, and our fourth quarter declines to $350,000 and $0.02 from $700,000 and $0.05, respectively. For the full year, EPS is now $0.19 versus a prior $0.22.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

V2X, Inc. (VVX) – Announces $100 Million Share Repurchase Program

Posted on by cpereira@noblefcm.com


Tuesday, May 13, 2025

V2X builds innovative solutions that integrate physical and digital environments by aligning people, actions, and technology. V2X is embedded in all elements of a critical mission’s lifecycle to enhance readiness, optimize resource management, and boost security. The company provides innovation spanning national security, defense, civilian, and international markets. With a global team of approximately 16,000 professionals, V2X enables mission success by injecting AI and machine learning capabilities to meet today’s toughest challenges across all operational domains.

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Hans Baldau, Associate Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

New Repurchase Program. Yesterday, V2X announced that its Board of Directors approved a share repurchase program under which the Company may purchase, from time to time, up to $100 million of the Company’s common stock for a three-year term ending on May 12, 2028.

Why? According to management, the share repurchase program reflects the strength of the business and management’s commitment to enhancing shareholder returns through a disciplined capital allocation strategy. As of yesterday’s close, the $100 million represents approximately 6.1% of the outstanding shares. To remind investors, private equity firm AIP owns about 45% of the outstanding shares.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Gyre Therapeutics, Inc (GYRE) – 1Q25 Highlighted By Product Launch With Phase 3 Data Expected In 2Q25

Posted on by cpereira@noblefcm.com


Tuesday, May 13, 2025

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

1Q25 Reported With Product Launch and Clinical Trial Updates. Gyre reported Net Income of $3.7 million with Net Income Attributable to Common Shareholders of $2.7 million or $(0.03) per share. Data analysis for the Phase 3 Hydronidone trial in CHB-ALF (chronic hepatitis B-associated liver fibrosis) is ongoing, with a data announcement expected during 2Q25. The company also launched avatrombopag in China and plans to launch nintedanib during 2Q25. The cash balance on March 31, 2025 was $51.3 million.

Product Sales Declined But Gross Margin Was As Expected. Product sales were $22.1 million, a decline from $27.8 million in 4Q24. The decline in sales of Etuary, its drug for ITP, was attributed to the economic conditions in China and the shift in marketing resources away from Etuary and toward the new products, nintedanib and avatrombopag. Gross Margin of 96% was as we expected despite lower product volume.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

SelectQuote (SLQT) – Prescription for Profit: Targets Pharmacy Margin Expansion

Posted on by cpereira@noblefcm.com


Tuesday, May 13, 2025

Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

FY Q3 results. The company reported fiscal Q3 revenue of $408.2 million, largely in line with our estimate of $417.0 million. Adj. EBITDA of $37.7 million was 10% lower than our estimate of $41.8 million, the variance largely due to higher cost of revenue.

Focusing on Pharmacy efficiency. In April, the company opened its new fulfillment center in Kansas, which is expected to drive higher profitability in the Healthcare Services segment over the long-term through newer technology and machinery. We expect the new facility to be a drag on profitability over the next quarter or so, however, due to the investments the company is making in the facility. The launch of the new facility aligns with the company’s goal to focus more on Healthcare Service profitability, given the scale that the segment has already achieved (approx. 106k SelectRx members). 

Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Seanergy Maritime (SHIP) – Updating 2025 Estimates; Rating Remains an Outperform

Posted on by cpereira@noblefcm.com


Tuesday, May 13, 2025

Seanergy Maritime Holdings Corp. is a prominent pure-play Capesize shipping company listed in the U.S. capital markets. Seanergy provides marine dry bulk transportation services through a modern fleet of Capesize vessels. The Company’s operating fleet consists of 18 vessels (1 Newcastlemax and 17 Capesize) with an average age of approximately 13.4 years and an aggregate cargo carrying capacity of approximately 3,236,212 dwt. Upon completion of the delivery of the previously announced Capesize vessel acquisition, the Company’s operating fleet will consist of 19 vessels (1 Newcastlemax and 18 Capesize) with an aggregate cargo carrying capacity of approximately 3,417,608 dwt. The Company is incorporated in the Marshall Islands and has executive offices in Glyfada, Greece. The Company’s common shares trade on the Nasdaq Capital Market under the symbol “SHIP”.

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Hans Baldau, Associate Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Updating first quarter estimates. We are revising our first quarter 2025 adjusted EBITDA and EPS estimates to $6.1 million and a loss of $0.38, respectively, from $6.0 million and a loss of $0.39. The revisions are driven by fewer dry-docking days during the quarter and an increase in operating days to 1,716 from 1,691. We also expect lower general and administrative costs, though this benefit is partially offset by higher vessel expenses tied to an increase in estimated ownership days.

Full year 2025 estimates. We are lowering our adjusted EBITDA and EPS estimates to $68.1 million and $0.59, down from $79.6 million and $1.17, respectively. The downward revisions reflect lower time charter rates and fewer operating days of 7,241 compared to our previous estimate of 7,391 due to an increase in the number of dry-docking days during the year. We have lowered our total revenue forecast to $142.5 million from $154.9 million. We modestly lowered our operating expense estimate to $111.7 million from $113.2 million, driven by expectations for lower general and administrative costs.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Saga Communications (SGA) – A Long Digital Runway

Posted on by cpereira@noblefcm.com


Tuesday, May 13, 2025

Saga Communications, Inc. is a broadcast company whose business is primarily devoted to acquiring, developing and operating radio stations. Saga currently owns or operates broadcast properties in 27 markets, including 79 FM and 33 AM radio stations. Saga’s strategy is to operate top billing radio stations in mid sized markets, defined as markets ranked (by market revenues) from 20 to 200. Saga’s radio stations employ a myriad of programming formats, including Active Rock, Adult Album Alternative, Adult Contemporary, Country, Classic Country, Classic Hits, Classic Rock, Contemporary Hits Radio, News/Talk, Oldies and Urban Contemporary. In operating its stations, Saga concentrates on the development of strong decentralized local management, which is responsible for the day-to-day operations of the stations in their market area and is compensated based on their financial performance as well as other performance factors that are deemed to effect the long-term ability of the stations to achieve financial objectives. Saga began operations in 1986 and became a publicly traded company in December 1992. The stock trades on NASDAQ under the ticker symbol “SGA”.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Favorable Digital growth outlook. Digital revenues are expected to accelerate to 18% revenue growth in Q2 versus 13.5% in Q1. Year to date, the company generated $5.5 million in digital revenue, surpassing the $5.0 million generated for full year 2024. We believe that the company’s Digital businesses should grow faster than industry averages.

Q1 Overview. The company reported Q1 revenue of $24.2 million and an adj. EBITDA loss of $0.5 million, both of which declined over the prior year period, but were modestly better than our estimates of $23.0 million and a loss of $1.1 million.  Notably, the company is focused on its blended digital growth strategy and improving profitability. We believe the company’s strategic actions are a step in the right direction for returning toward revenue and adj. EBITDA growth.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

NN, Inc. (NNBR) – Post Call Commentary – Transformation Progressing

Posted on by cpereira@noblefcm.com


Tuesday, May 13, 2025

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Hans Baldau, Associate Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Transformation Plan on Track. The enterprise transformation is now roughly 70% complete. Notably, the diversification is away from the automotive industry. Of the $160 million (peak value) of new wins over the past seven quarters, one-quarter are non-auto, and about half of the pipeline is now in non-auto verticals.

New Business. NN shifted the business development focus to closing and winning immediate ramp up sales, given the softness in certain end markets. The Company now has 120 programs that are ramping up this year worth $55 million in annualized sales, an increase over the 50 programs reported at the end of 4Q24.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Sky Harbour Group (SKYH) – Initiation of Coverage: A Long Cashflow Growth Runway

Posted on by cpereira@noblefcm.com


Monday, May 12, 2025

Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Initiating coverage with an Outperform rating and $23 price target. Sky Harbour Group (NYSE: SKYH) is a specialized aviation infrastructure developer focused on private and business aviation hangar facilities. It develops premium-grade hangar campuses under long-term ground lease agreements. With low land costs, tax-exempt financing, and strong tenant demand, we believe SKYH is positioned to deliver robust rental revenue growth and long-term free cash flow generation.

High-margin leasing model. Sky Harbour leases airport land at favorable long-term rates that are often under $1 per square foot annually. While only a fraction (1/4-1/3) of the land footprint is usable as rentable hangar space, this space can command upwards of $40 per square foot in rent. This creates a significant spread for SKYH. Furthermore, the company owns a prefabricated steel manufacturer, allowing for cost controls and delivery reliability. 


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Ocugen (OCGN) – 1Q25 Reported With All Three Main Clinical Trials On Schedule

Posted on by cpereira@noblefcm.com


Monday, May 12, 2025

Ocugen, Inc. is a biotechnology company focused on developing and commercializing novel gene therapies, biologicals, and vaccines. The lead product in its gene therapy program, OCU400, is in Phase 1/2 clinical trials for retinitis pigmentosa.

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Clinical Programs Meet Or Beat Expected Timeframes. Ocugen reported a 1Q25 loss of $15.4 million or $(0.05) per share, consistent with our estimates. The company’s three clinical trial continue to progress on schedule, with the first BLA application expected in mid-2026. Its fourth product, OCU200, initiated Phase 1 patient treatment during the quarter. Cash balance on March 31 was $38.1 million, projected to fund operations through early FY2026.

OCU400 Trial Continues To Lead The Way. The OCU400 liMeliGhT (pronounced “Limelight”) Phase 3 trial in RP continues to enroll patients, with completion expected around YE2025. The study enrolls patients over 5 years of age with any combination of over 100 mutations that cause RP. These patients are at stages ranging from early to advanced RP.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

MariMed Inc. (MRMD) – Making Progress

Posted on by cpereira@noblefcm.com


Monday, May 12, 2025

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Moving Forward. MariMed brands continue to capture more share across the markets served. The Company expanded into 70 new storefronts in the quarter. Although MariMed’s brands are already top sellers in their markets, we believe there is a significant opportunity to seize additional market share.

1Q25. Revenue in the first quarter of 2025 of $38 million was virtually unchanged from the first quarter of 2024. We had projected $38.8 million. Adjusted EBITDA was $2.56 million, down from $4.66 million last year. Reported net loss was $5.4 million, or $0.01/sh, compared to a net loss of $1.3 million, or breakeven, last year.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.